Drug Discount Review Boards Proposed by Biden Health Agency (2)

The Biden administration proposed Tuesday to revise the process behind an outlet for pharmaceutical companies to resolve price fights for those participating in the 340B drug discount program.

The federal 340B drug pricing program requires drugmakers to discount drugs for hospitals, community health centers, and other providers that support low-income populations.

Disputes between providers and pharmaceutical companies such as AstraZeneca were in limbo as the industry waited for the Biden administration to replace an administrative dispute resolution board.

The proposed rule (0906-AB28) signals that the wait may soon be over. It also ushers in “some significant changes” from ...